Pub. Date : 2022 Mar 8
PMID : 35259259
3 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | FDA Approval Summary: Ivosidenib for the treatment of patients with advanced unresectable or metastatic, chemotherapy refractory cholangiocarcinoma with an IDH1 mutation. | ivosidenib | isocitrate dehydrogenase (NADP(+)) 1 | Homo sapiens |
| 2 | On August 25, 2021, the FDA approved ivosidenib for the treatment of adult patients with unresectable locally advanced or metastatic hepatocellular isocitrate-dehydrogenase-1 (IDH1) mutated cholangiocarcinoma (CCA) as detected by an FDA-approved test with disease progression after 1-2 prior lines of systemic therapy for advanced disease. | ivosidenib | isocitrate dehydrogenase (NADP(+)) 1 | Homo sapiens |
| 3 | On August 25, 2021, the FDA approved ivosidenib for the treatment of adult patients with unresectable locally advanced or metastatic hepatocellular isocitrate-dehydrogenase-1 (IDH1) mutated cholangiocarcinoma (CCA) as detected by an FDA-approved test with disease progression after 1-2 prior lines of systemic therapy for advanced disease. | ivosidenib | isocitrate dehydrogenase (NADP(+)) 1 | Homo sapiens |